Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
Authors' conclusion
This post hoc study indicates that semaglutide may have beneficial effects on primary DKD prevention in people with T2D.
Study context
- Population
- Participants with T2D from SUSTAIN 6 without diabetic kidney disease (DKD) at baseline, grouped by baseline DKD risk (validated model)952 high DKD risk
- Participants
- 1,139 participants
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Proportion of participants who developed DKD (UACR ≥30 mg/g and/or eGFR <60 mL/min/1.73 m²)
Methodological detailspost hoc, randomized, double-blind, placebo-controlled
- Post hoc
- Randomized
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Developed DKD
Semaglutide vs PlaceboOdds ratio (95% CI)P value
Total population
0.56(0.42–0.74)
P < 0.0001High DKD risk population
0.51(0.38–0.69)
P < 0.0001- Developed DKD, total population
- 28.7%
- NNT for semaglutide in high DKD risk population
- 7
Further findings
Drivers of effect
- Beneficial effects of semaglutide largely driven by urinary albumin/creatinine ratio (UACR) changes
Original publication
Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial. Diabetes Obes Metab. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →